Anticoagulation plus batroxobin for acute cerebral venous thrombosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Seventy-two adults with neuroimaging-confirmed acute cerebral venous thrombosis within 30 days of symptom onset were randomized using a computer-generated, center-stratified sequence. Participants were assigned across three groups with experimental and control arms allocated 1:1 within each group and then pooled for overall comparison. Allocation was concealed with sealed opaque envelopes and the trial was conducted with patients, families, treating clinicians, and outcome assessors blinded to treatment. All participants received standard anticoagulant therapy and the experimental arms additionally received batroxobin.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged ≥18 years;
2. Neuroimaging confirmed acute CVT;
3. Symptoms onset was within 30 days prior to enrollment;
4. Signed the informed consent form.

Exclusion Criteria:

1. Patients with bleeding (including those with bleeding disorders due to coagulation and vascular disorders, active peptic ulcers, suspected intracranial hemorrhage, thrombocytopenic purpura, hemophilia, during menstruation, during surgery, urinary tract bleeding, hemoptysis, premature delivery, miscarriage, women immediately after delivery and during the puerperium with bleeding from the sexual organs, etc.);
2. Recently operated patients
3. Patients with a potential for bleeding (such as those with visceral tumors, diverticulitis of the digestive tract, colitis, subacute bacterial endocarditis, severe hypertension, and severe diabetes, etc.);
4. Those who are currently taking anticoagulant drugs and platelet function inhibitors (such as aspirin) and those who are using antifibrinolytic agents;
5. Those with a pre-medication fibrinogen concentration lower than 100 mg/dl;
6. Patients with severe liver or kidney dysfunction and other conditions such as papillary muscle rupture, ventricular septal perforation, cardiogenic shock, and multiple organ failure.
7. Those who have a history of allergy to this preparation.

Where it's running

• Xuanwu Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Ran Meng
• Email: victor65@126.com
• Phone: +86-10-83199280

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Danang Cerebral Venous Thrombosis Registry

  This registry collects information on adults with cerebral venous thrombosis admitted to Danang Hospital to see how the condition presents, what imaging shows, risk factors, and how patients recover.

  Recruiting Da Nang Hospital · Da Nang, Da Nang · NCT07890675

• Anticoagulation Plus Tocilizumab for Acute Cerebral Venous Thrombosis

  This study tests whether adding a single dose of tocilizumab to standard blood thinners helps people with acute cerebral venous thrombosis.

  Recruiting Capital Medical University · Beijing, Beijing Municipality · NCT07801638

• DOAC treatment outcomes for cerebral venous thrombosis in Vietnam

  This project will try direct oral anticoagulants (dabigatran or rivaroxaban) in adults with cerebral venous thrombosis to see if they are safe and effective in routine care.

  Recruiting Bach Mai Hospital · Hanoi, Hanoi · NCT07083609

• Evaluating the safety and effectiveness of edoxaban and rivaroxaban for treating cerebral venous thrombosis in Chinese patients

  This study is testing whether two blood thinners, edoxaban and rivaroxaban, are safe and effective for treating cerebral venous thrombosis in Chinese patients aged 18 to 80.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT06947707

• Using direct oral anticoagulants to treat cerebral venous thrombosis

  This study is testing whether a new type of blood thinner called direct oral anticoagulants can safely and effectively treat people with cerebral venous thrombosis.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT04660747

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.